

ranibizumab

Medicare Part B Drug Policy

- Medicare coverage is limited to items and services that are reasonable and necessary for the diagnosis or treatment of an illness or injury (and within the scope of a Medicare benefit category).
- Medicare Benefit Policy Manual - Pub. 100-02, Chapter 15, Section 50, describes national policy regarding Medicare guidelines for coverage of drugs and biologicals.
- Blue Shield of California (BSC) follows Medicare statutes, regulations, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and policy articles for determining coverage for Part B drug requests when applicable.
- BSC Medicare Part B Drug Policies will be used when coverage criteria are not fully established or there is an absence of any applicable Medicare statutes, regulations, NCDs or LCDs.

Drug Details

USP Category: OPHTHALMIC AGENTS

Mechanism of Action: a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endo

HCPCS:

J2778:Injection, ranibizumab, 0.1 mg

Q5124:Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg

Q5128:Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg

How Supplied:

Byooviz

20 mg/2 mL single-dose vial

Single-dose glass vial provides 0.05 mL for intravitreal injections: 10 mg/mL solution (0.5 mg dose)

Cimerli

0.3 mg (Single-use vial)

0.5 mg (Single-use vial)

Lucentis

0.3 mg (Single-use vial or syringe)

0.5 mg (Single-use vial or syringe)

Condition(s) listed in policy (see coverage criteria for details)

- [Diabetic Macular Edema \(DME\) or Diabetic Retinopathy](#)
- [Macular Edema Secondary to Retinal Vein Occlusion](#)
- [Myopic Choroidal Neovascularization](#)
- [Neovascular \(Wet\) Age-Related Macular Degeneration \(AMD\)](#)

Any request for a condition not listed in policy must meet the definition of a medically accepted indication. Section 1861(t)(2)(B) of the Act defines "medically-accepted indication," as any use of a prescription drug or biological product which is approved under the Federal Food, Drug, and

Cosmetic Act, or the use of which is supported by one or more citations included (or approved for inclusion) in one or more of the CMS approved compendia.

Special Instructions and Pertinent Information

Provider must submit documentation (such as office chart notes, lab results or other clinical information) to ensure the member has met all medical necessity requirements.

Coverage Criteria

The following condition(s) require Prior Authorization/Preservice:

Diabetic Macular Edema (DME) or Diabetic Retinopathy

Meets medical necessity if all the following are met:

1. Request is for Cimerli or Lucentis

Covered Doses:

Up to 0.3 mg once a month injected into affected eye

Coverage Period:

Yearly

ICD-10: (X= 0-9)

E08.3XXX, E09.3XXX, E10.3XXX, E11.3XXX, E13.3XXX

Macular Edema Secondary to Retinal Vein Occlusion

Meets medical necessity if all the following are met:

Covered Doses:

Up to 0.5 mg once a month injected into affected eye

Coverage Period:

Yearly

Myopic Choroidal Neovascularization

Meets medical necessity if all the following are met:

Covered Doses:

Up to 0.5 mg once a month injected into affected eye

Coverage Period:

Yearly

ICD-10:

H35.059

Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Meets medical necessity if all the following are met:

Covered Doses:

ranibizumab

Effective: 03/01/2025

Up to 0.5 mg once a month injected into affected eye

Coverage Period:

Yearly

Additional Information

Summary of Evidence

The contents of this policy were created after examining the following resources:

1. The prescribing information for Byooviz, Cimerli, and Lucentis
2. CMS approved compendium in accordance with the accepted compendia ratings listed:
 - a. Micromedex DrugDex - Class I, Class IIa, of Class IIb
 - b. American Hospital Formulary Service-Drug Information (AHFS-DI) - supportive narrative text

Explanation of Rationale:

- Support for FDA-approved indications can be found in the manufacturer’s prescribing information.

References

1. CMS Benefit Policy Manual. Chapter 15; § 50 Drugs and Biologicals
2. Medicare Coverage Database. Available at <https://www.cms.gov/Medicare-Coverage-Database/search.aspx>
3. Social Security Act (Title XVIII) Standard References, Sections: 1862(a)(1)(A) Medically Reasonable & Necessary; 1862(a)(1)(D) Investigational or Experimental; 1833(e) Incomplete Claim; 1861(t) (1) Drugs and Biologicals
4. AHFS®. Available by subscription at <http://www.lexi.com>
5. Byooviz™ (ranibizumab-nuna) [Prescribing Information]. Cambridge, MA: Biogen Inc.; 10/2023.
6. Cimerli™ (ranibizumab-eqrn) [Prescribing information]. Redwood City, CA: Coherus Biosciences, Inc.; 11/2022.
7. DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
8. Lucentis® (ranibizumab) [Prescribing information]. South San Francisco, CA: Genentech, Inc., 8/2023.

Review History

Date of Last Annual Review: 1Q2025

Changes from previous policy version:

- New part B policy

*Blue Shield of California Medication Policy to Determine Medical Necessity
Reviewed by P&T Committee*

The company complies with applicable state laws and federal civil rights laws and does not discriminate, exclude people, or treat them differently on the basis of race, color, national origin, ethnic group identification, medical condition, genetic information, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, mental disability, or physical disability. La compañía cumple con las leyes de derechos civiles federales y estatales aplicables, y no discrimina, ni excluye ni trata de manera diferente a las personas por su raza, color, país de origen,

ranibizumab

Effective: 03/01/2025

identificación con determinado grupo étnico, condición médica, información genética, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad, ni discapacidad física ni mental. 本公司遵守適用的州法律和聯邦民權法律，並且不會以種族、膚色、原國籍、族群認同、醫療狀況、遺傳資訊、血統、宗教、性別、婚姻狀況、性別認同、性取向、年齡、精神殘疾或身體殘疾而進行歧視、排斥或區別對待他人。